Rick E Winningham is Chief Executive Officer and Chairman of the Board of Directors of Theravance Biopharma. Mr. Winningham is also Chief Executive Officer and a member of the Board of Directors of Theravance, Inc. since October 2001, and was appointed Chairman of the Board of Directors of Theravance, Inc. in April 2010. From 1997 to 2001 he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen-year period with BMS and its predecessor, Bristol-Myers, Mr. Winningham held various U.S. and global management positions. During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol®, Paraplatin®, Zerit®, Videx®, Reyataz®, and Abilify®.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University. He is the Chairman of the Board of Directors of California Healthcare Institute (CHI) and a member of the Board of Directors of Jazz Pharmaceuticals. Mr. Winningham is also a member of Biotechnology Industry Organization’s Board of Directors, serving on the Health Section Governing Board and Board Standing Committee on Reimbursement.
Frank Pasqualone joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance, Inc. as Senior Vice President, Operations in January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.
Jeffrey D. Jonker joined Theravance Biopharma as Senior Vice President, Corporate and Business Development in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance as Senior Vice President, Corporate Business Development in October 2013. Prior to joining Theravance, Mr. Jonker served as Chief Business Officer of Satori Pharmaceuticals. Previously, he held senior business development and corporate strategy positions with Gloucester Pharmaceuticals and Genentech, Inc. Prior to Genentech, Mr. Jonker was an attorney in the Technology Transactions Group of Wilson, Sonsini, Goodrich & Rosati, representing clients in biotech, life sciences and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Brett K. Haumann joined Theravance Biopharma as Vice President, Clinical Development and Operations in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance as Vice President, Clinical Development in October 2013. Prior to joining Theravance, Dr. Haumann served as Chief Medical Officer at Circassia Limited. Previously, Dr. Haumann held senior positions at GlaxoSmithKline, including Medicines Development Leader and Vice President Clinical Development. Dr. Haumann has more than 15 years of experience in the discovery and development of pulmonary and allergy medicines. Dr. Haumann completed his M.D. at the University of Witwatersrand Medical School, South Africa and holds an M.B.A. from Open University, United Kingdom.
Renee D. Gala joined Theravance Biopharma as Vice President, Finance in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance in June 2006, where she held various roles in the finance organization before being promoted to Vice President of Finance in January 2013. From 2001 to 2006, Ms. Gala worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development. Prior to joining Eli Lilly, she spent seven years in the energy industry in the United States and internationally in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Gala earned a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
Heather Shane joined Theravance Biopharma as Vice President and Assistant General Counsel in June 2014 in connection with the spin-off from Theravance, Inc., after joining Senior Director and Assistant General Counsel in September 2005 and beingpromoted to Vice President and Assistant General Counsel in February 2011. Prior to joining Theravance, she was a corporate attorney at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP where she focused on private financings, fund formations, mergers & acquisitions and public offerings. Ms. Shane graduated from the University of California at Santa Barbara with a B.A. in English Literature and obtained her J.D. from New York University School of Law.